Compounded semaglutide & tirzepatide
for meaningful weight loss.
Semaglutide and tirzepatide are clinically studied GLP-1 receptor agonists prescribed to help reduce appetite and support meaningful weight loss. PureForty makes access straightforward — no subscriptions, no hidden costs.
Semaglutide is a GLP-1 receptor agonist — a class of medication that mimics the GLP-1 hormone your body naturally produces after eating. It works primarily by slowing gastric emptying, reducing appetite, and signaling satiety to the brain.
Originally developed for type 2 diabetes management, semaglutide has been extensively studied for its effects on body weight in clinical trials. It is administered as a once-weekly subcutaneous injection.
How It Works
GLP-1 receptor agonists bind to receptors in the gut and brain that regulate food intake and energy balance. By activating these receptors, semaglutide reduces appetite, increases the feeling of fullness, and slows the rate at which food leaves the stomach — leading to reduced caloric intake over time.
Key Points
From the Research
Semaglutide for weight management has been studied in large-scale clinical trials published in peer-reviewed journals including The New England Journal of Medicine. Research has examined its effects on body weight, cardiometabolic markers, and tolerability. Consult the medical literature and your clinician for information specific to your situation.
Known Side Effects
Side effects are common, especially during dose escalation. This is not a complete list — discuss all risks with your clinician before starting treatment.
Common (GI-related)
- Nausea — most frequent, especially in early weeks
- Vomiting
- Diarrhea or constipation
- Stomach pain or discomfort
- Reduced appetite (expected effect)
Less Common / Serious
- Fatigue or tiredness
- Headache
- Dizziness
- Injection site reactions
- Gallbladder-related issues (less common)
- Pancreatitis (rare — seek immediate care if severe abdominal pain)
Seek immediate medical attention if you experience severe abdominal pain, vision changes, or signs of allergic reaction. Tell your clinician about all medications you take. Not for use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Tirzepatide is a dual agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual-action mechanism is clinically distinct from single GLP-1 agonists like semaglutide.
Like semaglutide, tirzepatide is administered as a once-weekly subcutaneous injection and is dosed on a gradual titration schedule. It has been studied in clinical trials for both type 2 diabetes and weight management.
Dual-Action Mechanism
GIP receptors play a role in fat storage and energy balance alongside the gut. By activating both GIP and GLP-1 receptors simultaneously, tirzepatide engages complementary pathways involved in appetite regulation and metabolism. This pharmacological distinction is the subject of ongoing clinical research.
Key Points
From the Research
Tirzepatide has been studied in clinical trials published in peer-reviewed journals including The New England Journal of Medicine and The Lancet. Research has examined outcomes in people with obesity with and without type 2 diabetes. The clinical evidence base for this medication class is actively evolving — discuss the current literature with your clinician.
Known Side Effects
The side effect profile for tirzepatide is similar to semaglutide, with GI effects being the most common. This is not a complete list.
Common (GI-related)
- Nausea — most frequent during titration
- Vomiting
- Diarrhea or constipation
- Stomach discomfort or pain
- Reduced appetite (expected effect)
Less Common / Serious
- Fatigue
- Injection site reactions
- Dizziness or headache
- Gallbladder disease
- Pancreatitis (rare)
- Thyroid-related concerns (see safety information below)
Same safety precautions apply as with semaglutide. Seek immediate care for severe symptoms. Inform your prescribing clinician of all medications and medical conditions.
A realistic
results timeline.
Individual results vary significantly based on starting weight, diet, activity level, and other factors. This is a general guide — not a guarantee.
Dose Initiation
You'll begin at the lowest dose. Most people experience some GI adjustment — nausea and mild discomfort are common and typically improve as your body adapts. Weight changes at this stage are modest. The goal is tolerability, not maximum effect.
Dose Escalation
Your clinician will guide dose increases on a schedule. Appetite reduction typically becomes more noticeable. Many people begin to see measurable weight changes during this phase. GI side effects often improve with each dose level over time.
Therapeutic Range
By months three to six, most patients have reached a maintenance dose. Clinically meaningful weight loss — defined as 5% or more of body weight — is the benchmark used in research. Some patients see more; some see less. Consistent diet and lifestyle habits matter.
Ongoing Progress
Weight loss from GLP-1 medications tends to plateau over time as a new equilibrium is reached. Ongoing clinical check-ins help assess whether to continue, adjust, or taper. Long-term use should be discussed with your prescribing clinician.
One price.
Everything included.
Consultation, medication, and shipping are all included. No add-ons, no fine print.
1-Month Supply
Includes: clinician consultation, medication, free shipping, secure messaging
Get Started3-Month Supply
Includes: clinician consultation, medication, free shipping, secure messaging
Get Started6-Month Supply
Includes: clinician consultation, medication, free shipping, secure messaging
Get StartedPricing shown is for compounded medication. Compounded drug products are not FDA-approved and have not been evaluated for safety, effectiveness, or quality by the FDA. Prescription required. Prices subject to change. FSA/HSA may be accepted — verify with your plan.
What's included
in every order.
There are no add-on fees. Everything you need from assessment to delivery is part of the price you see.
Clinician Consultation
A licensed US physician or NP reviews your health intake and determines if a prescription is appropriate.
Prescription Medication
Your prescribed medication, prepared by an accredited compounding pharmacy and shipped in temperature-controlled packaging.
Injection Supplies
Syringes, alcohol swabs, and administration instructions included with every shipment.
Secure Messaging
Message your care team with questions any time. Clinicians typically respond within 24 business hours.
Clinical Check-ins
Ongoing clinician oversight throughout your treatment cycle — not just at initiation. Dose adjustments as needed.
Free 2-Day Shipping
Every order ships with free expedited 2-day delivery. Cold-chain packaging where required. Tracking included.
What the research
shows about GLP-1.
These medications have been studied in peer-reviewed clinical trials. The following summarizes published research on the drug class — not PureForty's outcomes. Results in clinical trials may not reflect your individual experience.
Studies published in the New England Journal of Medicine found that GLP-1 receptor agonists demonstrated meaningful reductions in body weight in large randomized controlled trials — representing a clinically significant advance in the pharmacological treatment of obesity.
Based on STEP and SURMOUNT trial findings on semaglutide and tirzepatide. Full publications available at nejm.org. Consult your clinician for interpretation relevant to your situation.
Research published in The Lancet has characterized obesity as a complex, chronic disease and documented how pharmacological interventions targeting its underlying hormonal mechanisms have expanded the treatment landscape significantly over the past decade.
Reflecting The Lancet's published coverage of GLP-1 pharmacotherapy in obesity medicine. Full publications available at thelancet.com.
Harvard Health Publishing has explained that GLP-1 medications work differently from older weight-loss drugs — they target the hormonal signals that drive hunger and fullness rather than metabolism alone, which accounts for much of the clinical interest in this drug class.
Summarizing Harvard Health's published educational coverage on GLP-1 mechanisms. Not a clinical endorsement of any specific product or compounded formulation.
Important Note on Research Citations
The statements above summarize general published findings about the GLP-1 drug class. They are not endorsements of PureForty, compounded medications specifically, or any individual's expected outcomes. Clinical trial results were conducted with brand-name formulations under controlled conditions. Compounded formulations have not been evaluated by the FDA for safety, effectiveness, or quality. Talk to your clinician.
Important safety
information.
Read this before starting any GLP-1 medication. This is a summary — not a substitute for a conversation with your clinician.
Who should not use GLP-1 medications
These medications are not appropriate for everyone. Do not use semaglutide or tirzepatide if you have:
- A personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- A history of serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient
- Type 1 diabetes (unless specifically directed by a specialist)
- Are pregnant or planning to become pregnant
When to seek immediate care
Stop use and contact a healthcare provider immediately if you experience:
- Severe and persistent abdominal pain (possible pancreatitis)
- Signs of allergic reaction: rash, difficulty breathing, swelling of face/lips/throat
- Rapid heartbeat or heart palpitations
- Changes in vision
- Signs of low blood sugar (if also taking insulin or sulfonylureas)
- Symptoms of gallbladder disease: upper right abdominal pain, fever, jaundice
Drug interactions
Tell your clinician about all medications, supplements, and vitamins you take. Particular attention should be given to:
- Insulin or other blood sugar medications (risk of hypoglycemia)
- Oral medications that require precise absorption timing (gastric emptying effects)
- Warfarin or other anticoagulants
FDA compounding notice
Compounded drug products are not FDA-approved. They have not been evaluated by the FDA for safety, effectiveness, or quality. Compounding is regulated at the state and federal level. PureForty works with accredited compounding pharmacies, but patients should understand that compounded formulations differ from FDA-approved brand-name products.
Medication questions,
answered plainly.
Ready to start your
weight loss plan?
Complete a health intake online. A licensed clinician reviews it within 24 hours. If appropriate, your medication ships the same day.
Apply Now — Free AssessmentNot all applicants will be approved. Results vary. Compounded medications are not FDA-approved. PureForty is a telehealth platform — not a pharmacy.